Bevacizumab-tnjn (Avzivi)

Note: this is an FDA-approved biosimilar. The information below is reproduced from the Bevacizumab (Avastin) page, except for the details of FDA indication and the references.
==General information==
Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape,or the prescribing information.
==Diseases for which it is used==
*Carcinoma of unknown primary
*Anaplastic glioma
*Breast cancer
*Cervical cancer
*Cholangiocarcinoma
*Colorectal cancer
*Esophageal cancer
*Follicular lymphoma
*Glioblastoma
*Hepatocellular carcinoma
*Melanoma 
*Malignant pleural mesothelioma
*Neuroendocrine tumor
*Non-small cell lung cancer
*Ovarian cancer
*Pancreatic NET
*Renal cell carcinoma
*Small cell lung cancer
*Soft tissue sarcoma 
*Testicular cancer
*Endometrial cancer
*Vascular sarcoma
==History of changes in FDA indication==
*2023-12-06: Approved for metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
*2023-12-06: Approved for metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
*2023-12-06: Approved for first-line non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel.
*2023-12-06: Approved for recurrent glioblastoma in adults.
*2023-12-06: Approved for metastatic renal cell carcinoma in combination with interferon alfa.
*2023-12-06: Approved for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
*2023-12-06: Approved for epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.
==Also known as==
*Code name: BAT-1706
*Brand names: Avzivi
==References==
Category:Drugs
Category:Intravenous medications
Category:Neutral
Category:Anti-VEGF antibodies
Category:Carcinoma of unknown primary medications
Category:Anaplastic glioma medications
Category:Breast cancer medications
Category:Cervical cancer medications
Category:Cholangiocarcinoma medications
Category:Colorectal cancer medications
Category:Esophageal cancer medications
Category:Follicular lymphoma medications
Category:Glioblastoma medications
Category:Hepatocellular carcinoma medications
Category:Melanoma medications 
Category:Malignant pleural mesothelioma medications
Category:Neuroendocrine tumor medications
Category:Non-small cell lung cancer medications
Category:Ovarian cancer medications
Category:Pancreatic NET medications
Category:Renal_cell_carcinoma medications
Category:Small cell lung cancer medications
Category:Soft tissue sarcoma medications 
Category:Testicular cancer medications
Category:Endometrial cancer medications
Category:Vascular sarcoma medications
Category:FDA approved in 2023
Category:Biosimilars